BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies
{{output}}
Although BRIGHTLINE-1 was headlined as a "negative trial," brigimadlin showed clear biological activity, with median PFS of 8.4 months, ORR of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions,... ...